Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Blood (2019) 134 (23): 2036–2045.

https://doi.org/10.1182/blood.2019000069

Published: 2019

Includes: Supplemental data

Journal Articles

Clinical Characteristics of Elderly Chronic Myeloid Leukemia Patients in Korea; Based on the National Health Information Database

Jee Hyun Kong, MD, Tae-Hwa Go, Jung Yeon Lee, MD, Jieun Uhm, MD PhD, Shin Young Hyun, MD

Blood (2018) 132 (Supplement 1): 4262.

https://doi.org/10.1182/blood-2018-99-116158

Published: 2018

Journal Articles

NOVEL-1 st : Interim Analysis of a Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

Hwang Wen-Li, MD, Shao-Min Han, MD, Shyuann-Yuh Lin, MD, Ming-Chih Chang, MD, Li-Yuan Bai, PhD, Pei-Ching Hsiao, MD, Ching-Yuan Kuo, Yeu-Chin Chen, MD, Ta-Chih Liu, MD PhD, Po-Nan Wang, MD, Jyh-Pyng Gau, MD, Yee-Ming Lee, PhD, Fan-Chen Ku, Jih-Luh Tang, MD

Blood (2018) 132 (Supplement 1): 3019.

https://doi.org/10.1182/blood-2018-99-112342

Published: 2018

Journal Articles

Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States

Karen Seiter, MD, Dominick Latremouille-Viau, Annie Guerin, MS, Briana Ndife, MPH, Karen Habucky, PhD, George J Joseph, BPharm, MS, PhD, Irina Pivneva, PhD, Patrick Gagnon-Sanschagrin, MS, Derek H Tang, BSPharm, PhD

Blood (2017) 130 (Supplement 1): 3391.

https://doi.org/10.1182/blood.V130.Suppl_1.3391.3391

Published: 2017

Journal Articles

Nilotinib As Second-Line Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase: Thailand Experience

Kanchana Chansung, MD, Chittima Sirijerachai, MD, Arnuparp Lekhakula, MD MS, Pongtep Viboonjuntra, MDPhD, Pimjai Niparuck, MD, Teeraya Pauvilai, MD, Tontanai Numbenjapon, MD, Udomsak Bunworasate, MD, Weerasak Nawarawong, MD, Adisak Tantiworawit, MD, Tawatchai Suwanban, MD, Saengsuree Jootar

Blood (2016) 128 (22): 5448.

https://doi.org/10.1182/blood.V128.22.5448.5448

Published: 2016

Journal Articles

BP1001, a Novel Therapeutic for Chronic Myelogenous Leukemia

Ana Tari Ashizawa, PhD, Maro Ohanian, DO, Jorge E. Cortes, MD

Blood (2016) 128 (22): 4239.

https://doi.org/10.1182/blood.V128.22.4239.4239

Published: 2016

Journal Articles

The Real World Use of Bosutinib in Patients with Chronic Myeloid Leukaemia

Jane F. Apperley, MD, Jenny L. Byrne, FRCP FRCPath PhD, Graeme Smith, Simone Claudiani, Andrea Viqueira, Roxanne Ferdinand, Angela M Carter, Georgina Nock, Dragana Milojkovic

Blood (2016) 128 (22): 5435.

https://doi.org/10.1182/blood.V128.22.5435.5435

Published: 2016

Journal Articles

Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Elias Jabbour, Marina Konopleva, MD PhD, Miranda Lim, BSN, Sherry Pierce, BSN, BA, Susan O'Brien, MD, Bradley G. Somer, MD, Ana Tari, PhD, William Wierda, MD PhD, Srdan Verstovsek, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3801.

https://doi.org/10.1182/blood.V126.23.3801.3801

Published: 2015

Journal Articles

EUTOS Score Predicts Long-Term Outcome in Chronic Myeloid Leukemia Patients Transitioning from Pre-Imatinib Era to Imatinib upon Availability

Pratik Deb, MBBS, Uttam Nath, M.B.B.S., MD, D.M., Rajarshi Aich, M.B.B.S, Siddhartha Sankar Ray, M.B.B.S., MD, D.M., Prantar Chakrabarti, MBBS,MDDM

Blood (2015) 126 (23): 4023.

https://doi.org/10.1182/blood.V126.23.4023.4023

Published: 2015

Journal Articles

Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

Lei Chen, MD PhD, Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Roy Nitulescu, MSc, Patrick Gagnon-Sanschagrin, BSc

Blood (2015) 126 (23): 1596.

https://doi.org/10.1182/blood.V126.23.1596.1596

Published: 2015

Journal Articles

Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy

B. Douglas Smith, MD, Jun Liu, PhD, Dominick Latremouille-Viau, MSc, Zhou Zhou, MSc, Annie Guerin, MSc, Daniel Fernandez, MA, Dingdong Yi, BS, Xufei Wang, MA, Eric Q Wu, PhD, Shivani K Mhatre, MSc, Christopher H Keir, MD, Lei Chen, MD PhD

Blood (2014) 124 (21): 2618.

https://doi.org/10.1182/blood.V124.21.2618.2618

Published: 2014

Journal Articles

A Retrospective Analysis of Treatment Patterns in Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy after Imatinib

Blood (2014) 124 (21): 1293.

https://doi.org/10.1182/blood.V124.21.1293.1293

Published: 2014

Journal Articles

Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR 4.5 ) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update

Michael Mauro, MD, Jerald Radich, MD, Jorge E. Cortes, MD, Shaker Dakhil, MD, Christopher Keir, MD, Sandy Yi, Martha Wadleigh, MD, Vivian G. Oehler, MD, Thomas Ervin, MD, Stuart Goldberg, MD, Michael Savona, MD, FACP

Blood (2013) 122 (21): 4015.

https://doi.org/10.1182/blood.V122.21.4015.4015

Published: 2013

Journal Articles

Safety, Pharmacokinetics, and Efficacy Of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) In Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD, PhD, Elias Jabbour, MD, Marina Konopleva, MD, PhD, Susan O'Brien, MD, Alfonso Quintas-Cardama, MD, Bradley G. Somer, MD, Ana Tari, PhD, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2679.

https://doi.org/10.1182/blood.V122.21.2679.2679

Published: 2013

Journal Articles

Treatment Patterns Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting.

Kavita R Sail, MS, PhD, Lei Chen, MD, PhD, James Jackson, PharmD, MPH, Solveig G. Ericson, MD, PhD, Sally Haislip, RPh, Tamara Ibison, RN, James Gilmore, PharmD, Mansoor N Saleh, MD

Blood (2012) 120 (21): 3179.

https://doi.org/10.1182/blood.V120.21.3179.3179

Published: 2012

Journal Articles

Comparison of Treatment Changes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched From Imatinib to Nilotinib or Dasatinib As Second-Line Therapy

Alexander R. Macalalad, MD, Lei Chen, MD, PhD, Annie Guerin, MSc, Jiayuan Luo, MSc, Eric Qiong Wu, PhD, James D. Griffin, MD

Blood (2012) 120 (21): 4443.

https://doi.org/10.1182/blood.V120.21.4443.4443

Published: 2012

Journal Articles

Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey

Stuart L. Goldberg, MD, Lei Chen, MD, PhD, Solveig G. Ericson, MD, PhD, Alexander R. Macalalad, MD, Annie Guerin, MSc, Nathan Liu, MPH, Michael Kaminsky, BSc, Eric Qiong Wu, PhD

Blood (2012) 120 (21): 1685.

https://doi.org/10.1182/blood.V120.21.1685.1685

Published: 2012

Journal Articles

Monitoring Patterns and Subsequent Outcomes Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting

James Jackson, PharmD, MPH, Lei Chen, MD, PhD, Kavita R Sail, MS, PhD, Solveig G. Ericson, MD, PhD, Sally Haislip, RPh, Joyce Sharpe, RN, James Gilmore, PharmD, Mansoor N Saleh, MD

Blood (2012) 120 (21): 2066.

https://doi.org/10.1182/blood.V120.21.2066.2066

Published: 2012

Journal Articles

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

David T Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD, Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, MBChB, FRACP, FRCPA, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2012) 120 (21): 3771.

https://doi.org/10.1182/blood.V120.21.3771.3771

Published: 2012

Journal Articles

Assessment of Clinical Safety and Estimate of Survival in Iraqi Patients with Chronic Myeloid Leukemia Switched From Glivec (β-Crystalline Form of Imatinib Mesylate) to an α-Crystalline Copy of Imatinib Mesylate

Marc Botteman, MSc, MA, Matthew Magestro, Alaa Fadhil Alwan, MD, Paul W Manley, PhD, Oleg Zernovak, MD, Richard C. Woodman

Blood (2012) 120 (21): 4439.

https://doi.org/10.1182/blood.V120.21.4439.4439

Published: 2012

NARROW

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Clinical Characteristics of Elderly Chronic Myeloid Leukemia Patients in Korea; Based on the National Health Information Database

NOVEL-1 st : Interim Analysis of a Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States

Nilotinib As Second-Line Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase: Thailand Experience

BP1001, a Novel Therapeutic for Chronic Myelogenous Leukemia

The Real World Use of Bosutinib in Patients with Chronic Myeloid Leukaemia

EUTOS Score Predicts Long-Term Outcome in Chronic Myeloid Leukemia Patients Transitioning from Pre-Imatinib Era to Imatinib upon Availability

Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy

A Retrospective Analysis of Treatment Patterns in Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy after Imatinib

Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR 4.5 ) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update

Treatment Patterns Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting.

Comparison of Treatment Changes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched From Imatinib to Nilotinib or Dasatinib As Second-Line Therapy

Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey

Monitoring Patterns and Subsequent Outcomes Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

Assessment of Clinical Safety and Estimate of Survival in Iraqi Patients with Chronic Myeloid Leukemia Switched From Glivec (β-Crystalline Form of Imatinib Mesylate) to an α-Crystalline Copy of Imatinib Mesylate

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only